Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hepatitis C 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Liver Diseases 1

Interventions

Cyclophosphamide 240Rituximab 187fludarabine phosphate 129Etoposide 110Peripheral Blood Stem Cell Transplantation 108Mycophenolic Acid 94Filgrastim 91Melphalan 90Whole-Body Irradiation 88fludarabine 80Busulfan 80Tacrolimus 71Cytarabine 66Cyclosporine 66Radiotherapy 62Methotrexate 53Antilymphocyte Serum 53Granulocyte Colony-Stimulating Factor 51Vincristine 49Carmustine 48Doxorubicin 41Prednisone 37Thiotepa 33Bendamustine Hydrochloride 32Bortezomib 30Methylprednisolone 29Dexamethasone 28Stem Cell Transplantation 27thymoglobulin 26ibritumomab tiuxetan 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Non-Hodgkin × ledipasvir, sofosbuvir drug combination × Clear all
NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated
1 enrolled
Lymphoid

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡